Begin typing your search above and press return to search.
Volume: 17 Issue: 5 October 2019

FULL TEXT

CASE REPORT
Afibrinogenemia Acquired by Liver Transplant

Liver transplant is a life-saving procedure in patients with end-stage liver disease. However, this procedure may be associated with transmission of various deficiencies of proteins synthesized by the liver. Factor I (fibrinogen) deficiency is one of the rare inherited coagulation disorders with an extremely low risk of transmission by liver transplant. We report a case of a patient with no inherited coagulation disorders but who demonstrated disturbance of fibrinogen after liver transplant. This case highlights the ever-present risk of donor-to-recipient disease transmission during transplant and emphasizes the difficulty in procuring organs from donors in which standard blood tests are insufficient to determine the likelihood of this event.


Key words : Blood coagulation disorders, Fibrinogen, Inherited transmission

Introduction

The liver donor was a 34-year-old nullipara woman who was declared brain dead after spontaneous intracranial hemorrhage. Her past medical history was mainly unknown. The donor’s laboratory tests on admission showed prothrombin time of 17.3 seconds (normal range, 11-13 s), internationalized normalized ratio (INR) of 1.62, activated partial thromboplastin time of 32 seconds, and a normal platelet count, hemoglobin, and other routine tests. Ultrasonographic examination of the donor’s abdomen before organ procurement showed liver having normal parenchymal echogenicity without pathologic lesions. In addition, the donor’s pre-transplant biopsy did not reveal any pathologic findings, such as marked steatohepatitis, fibrosis, necrosis, or malignancy. Figure 1 shows histology of the liver taken by needle biopsy on the day of organ procurement.

The recipient was a 56-year-old man with end-stage liver disease secondary to hepatitis B. Model for End-Stage Liver Disease score was 29. Neither he nor his family reported a history of bleeding disorders. The patient underwent deceased-donor liver transplant in November 2014. Duration of the procedure was 6 hours, with total cold ischemic time of 189 minutes and total warm ischemic time of 52 minutes. There was no unusual bleeding during the operation. The total blood loss was 3.6 L. The patient was given 5 units of packed red blood cells and 8 units of fresh frozen plasma. The liver functioned well postoperatively, and the patient was extubated in the operating room. In the intensive care unit, the patient was maintained on tacrolimus-based immunosuppression therapy on postoperative day 1. He was given hepatitis B prophylaxis with hepatitis B immunoglobulin.

The coagulation profile on postoperative day 1, compared with the pretransplant findings, was at acceptable levels (partial thromboplastin time of 36 seconds, prothrombin time of 23.7 seconds, INR of 1.89, and platelet level of 74 × 109 L). However, postoperatively, the coagulation profile persistently fluctuated widely during the following days. An attempt was made to find the cause of this condition. Blood tests showed fibrinogen level of 2.058 μmol/L (70 mg/dL; reference range, 200-400 mg/dL), with other coagulation factor test results at normal ranges. The immunoreactive fibrinogen level in the plasma was low; therefore, a diagnosis of afibrinogenemia was made.

The patient was administered virally inactivated fibrinogen concentrate (human; Haemocomplettan P; CSL Behring, Marburg, Germany) intravenously at 1 g twice per week. Forty days after liver transplant, the patient was discharged with a prothrombin time of 19.3 seconds, activated partial thromboplastin time of 32 seconds, and INR of 1.62. Seventeen days later, the patient was admitted with severe swelling and a blue discoloration of his right hand. Figure 2 shows a view of the patient’s hand on readmission. A color Doppler ultrasonography of the hand was done, which did not show any venous thrombosis or arterial obstruction. The patient received a diagnosis of cellulitis and responded well to treatment with antibiotic therapy. During the 10 days of his hospitalization, he was given 10 units of fresh frozen plasma and 5 units of cryoprecipitate.

At about 10 months after transplant, the patient developed persistently abnormal serum amino-transferase levels. The hepatitis B viral load was undetectable on his quantitative real-time polymerase chain reaction test. A percutaneous liver biopsy was performed, confirming an episode of rejection of the graft, which responded to standard treatment with steroids. At present, the patient’s tests indicate good liver function. He has continued with fibrinogen concentrate treatment (1 g twice per week). His coagulation profile and fibrinogen level have remained within acceptable limits without any further coagulation problems. Figure 3 shows the results of the liver function tests and the coagulation profile after liver transplant.

Discussion

Disorders of fibrinogen may result from quantitative deficiencies or qualitative defects of proteins and/or a combination of the 2 (hypodysfibrinogenemia). Congenital afibrinogenemia has an estimated prevalence of 1 in 1 million. The prevalence of hypo-fibrinogenemia and dysfibrinogenemia is difficult to establish because of the large number of asymp-tomatic cases.1 Some types of hypofibrinogenemia are associated with liver disease in which the retention of abnormal fibrinogen in hepatocytes is the cause of the problem. Recently, some subgroups of fibrinogen disorders have emerged in which mutation in the fibrinogen γ-chain gene results in inherited hypofibrinogenemia with storage of defective fibrinogen in the endoplasmic reticulum of hepatocytes, leading to liver disease of variable severity in both children and adults.2

Gallastegui and associates3 reported the sub-sequent resolution of fibrinogen deficiency and restoration of hemostasis in a patient with congenital afibrinogenemia after orthotopic liver transplant. The coexistence of congenital afibrinogenemia and protein C deficiency has also been described, and both deficiencies were corrected with liver transplant. However, acquired deficiencies of coagulation factors may not always be benign. There is a reported case of acquired heterozygous protein C deficiency and dysfibrinogenemia after liver transplant that was associated with severe thrombotic complica-tions.4

Numerous cases of cutaneous manifestations of thrombosis-associated afibrinogenemia have been reported in the literature.5 In our case, the first cutaneous symptoms appeared about 1 month after starting fibrinogen concentrate (Haemocomplettan P). This disturbance may be mainly due to deposition of circulating immune complexes in the blood vessels, thus leading to vasculitis. The roles of fibrinogen and interference with the immune system are also worthy of further scrutiny.

Our review of the literature6-9 revealed that transmission of blood coagulation disorder from liver donor to recipient could lead to brain hemorrhage and brain death in donors. There is no specific screening procedure recommended for detection of these rare inherited genetic disorders in deceased donors with the absence of medical or family history. Thromboelastography is a useful test for detection of coagulation disorders. It shows the clot’s tensile strength and its rate of formation and stability. Thromboelastography tracing should be considered as a reasonable examination in such deceased donors for coagulation studies. We also recommend that plasma samples should be collected from the donor at the time of organ procurement and also from the recipient immediately before liver transplant. These samples should be frozen and stored for later coagulation studies and further evaluation.


References:

  1. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39(6):585-595.
    CrossRef - PubMed
  2. Asselta R, Robusto M, Braidotti P, et al. Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen γ-module. J Thromb Haemost. 2015;13(8):1459-1467.
    CrossRef - PubMed
  3. Gallastegui N, Kimble EL, Harrington TJ. Resolution of fibrinogen deficiency in a patient with congenital afibrinogenemia after liver transplantation. Haemophilia. 2016;22(1):e48-51.
    CrossRef - PubMed
  4. Cransac M, Carles J, Bernard PH, et al. Heterozygous protein C deficiency and dysfibrinogenemia acquired by liver transplantation. Transpl Int. 1995;8(4):307-311.
    CrossRef - PubMed
  5. Girard C, Guillot B, Biron C, Lavabre-Bertrand T, Navarro R, Bessis D. Digital skin necrosis in congenital afibrinogenaemia associated with hepatitis C virus infection, mixed cryoglobulinaemia and anticardiolipin antibodies. Acta Derm Venereol. 2005;85(1):56-59.
    CrossRef - PubMed
  6. Guy SR, Magliocca JF, Fruchtman S. et al. Transmission of factor VII deficiency through liver transplantation. Transpl Int. 1999;12(4):278-280.
    CrossRef - PubMed
  7. Brunetta DM, Carneiro-Silva FA, Vasconcelos JB, et al. Hemophilia B acquired through liver transplantation. Liver Transpl. 2016;22(2):254-256.
    CrossRef - PubMed
  8. Osborn NK, Ustundag Y, Zent CS, Wiesner RH, Rosen CB, Narayanan Menon KV. Factor XII deficiency acquired by orthotopic liver transplantation: case report and review of the literature. Am J Transplant. 2006;6(7):1743-1745.
    CrossRef - PubMed
  9. Yankol Y, Mecit N, Kanmaz T, Acarli K, Kalayoglu M. Acquired factor XI deficiency: a rare complication after liver transplantation. Transplant Proc. 2015;47(1):179-181.
    CrossRef - PubMed


Volume : 17
Issue : 5
Pages : 692 - 694
DOI : 10.6002/ect.2016.0338


PDF VIEW [177] KB.

From the 1Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; and the 2Department of Pathology, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Acknowledgements: The authors have no sources of funding for this study and have no conflicts of interest to declare. We thank Z. Sadeghnezhad at the organ transplant center of Mashhad University of Medical Sciences for research assistance.
Corresponding author: Soheila Milani, Surgical Oncology Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Phone: +98 51 38022677
E-mail: drmilanis7@gmail.com